EPS-1421 / Enanta Pharma - LARVOL DELTA

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Businesswire) - "KIT inhibitors: (i) Enanta’s lead development candidate, EPS-1421:...The Company is currently conducting scale-up activities and IND enabling studies; (ii) STAT6 Inhibitors:...The Company plans to select a STAT6 development candidate in the second half of 2025; (iii) Enanta plans to expand its immunology pipeline with the introduction of a third program in 2025."

Pipeline update • Preclinical • Immunology

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 (Businesswire) - "EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications...Enanta is conducting scale-up activities and IND enabling studies in 2025...The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases...The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025....Enanta plans to expand its presence in immunology with the introduction of a third program in 2025."

Pipeline update • Preclinical • Atopic Dermatitis • Chronic Spontaneous Urticaria